KLRS Kalaris Therapeutics Inc.
Price (delayed)
$8.07
Market cap
$40.7M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.73
Enterprise value
-$77.59M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The
Highlights
Kalaris Therapeutics's debt has plunged by 100% YoY
KLRS's EPS has soared by 72% YoY and by 42% QoQ
The quick ratio has dropped by 74% since the previous quarter
The equity has declined by 22% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of KLRS
Market
Valuations
Earnings
Shares outstanding
5.04M
Market cap
$40.7M
Enterprise value
-$77.59M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.36
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$65.44M
Net income
-$58.77M
EBIT
-$58.77M
EBITDA
-$58.62M
Free cash flow
-$67.71M
Per share
Balance sheet
Liquidity
EPS
-$11.73
EPS diluted
-$11.73
Free cash flow per share
-$13.52
Book value per share
$22.56
Revenue per share
$0
TBVPS
$23.67
Total assets
$118.55M
Total liabilities
$5.24M
Debt
$0
Equity
$113.31M
Working capital
$113.31M
Debt to equity
0
Current ratio
22.63
Quick ratio
22.58
Net debt/EBITDA
2.02
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-45.5%
Return on equity
-49.5%
Return on invested capital
-235.4%
Return on capital employed
-51.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KLRS stock price
How has the Kalaris Therapeutics stock price performed over time
Intraday
0.88%
1 week
-12.38%
1 month
-17.65%
1 year
-54.28%
YTD
-16.46%
QTD
0.5%
Financial performance
How have Kalaris Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.44M
Net income
-$58.77M
Gross margin
N/A
Net margin
N/A
The net income has soared by 69% year-on-year and by 41% since the previous quarter
The operating income has soared by 67% YoY and by 40% from the previous quarter
Growth
What is Kalaris Therapeutics's growth rate over time
Valuation
What is Kalaris Therapeutics stock price valuation
P/E
N/A
P/B
0.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
KLRS's EPS has soared by 72% YoY and by 42% QoQ
The price to book (P/B) is 87% less than the 5-year quarterly average of 2.6 and 50% less than the last 4 quarters average of 0.7
The equity has declined by 22% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Kalaris Therapeutics business performance
KLRS's return on equity has surged by 50% year-on-year and by 37% since the previous quarter
Kalaris Therapeutics's return on invested capital has decreased by 46% YoY and by 19% QoQ
The return on assets rose by 42% year-on-year and by 33% since the previous quarter
Dividends
What is KLRS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KLRS.
Financial health
How did Kalaris Therapeutics financials performed over time
KLRS's total liabilities has dropped by 88% year-on-year
The quick ratio has dropped by 74% since the previous quarter
Kalaris Therapeutics's debt is 100% less than its equity
Kalaris Therapeutics's debt has plunged by 100% YoY
KLRS's debt to equity has dropped by 100% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.